625results about How to "Sustained release" patented technology

There is disclosed a medical device for implantation that acts to prevent transmission of infectious agents. Specifically, the present invention provides implantable devices, such as catheters or living skin matrices or wound dressings, for insertion into various body cavities or over wound sites to confer to the site microbicidal or virucidal activity. Devices in the disclosure designed as vaginal inserts also exhibit contraceptive spermicidal activity. The coated devices or devices having the inventive polymeric material interspersed throughout are formed into appropriate shapes according to their contemplated uses (such as catheters or Foley catheters). Further, the present invention provides devices for providing therapeutic anti-microbial activity into an infected body cavity or on an infected wound site.

Methods and compositions are disclosed for the preparation of free radical scavenging polymers and polymer films functionalized with antioxidants. Enzymatic and chemical tailoring of monomers with antioxidants followed by enzymatic polymerization is described. These antioxidant functionalized polymers can increase shelf life and quality of food products, as well as, increase effectiveness of pharmaceutical agents when used as packaging or as coatings on packaging for oxygen sensitive materials. The novel enzymatic covalent coupling of antioxidants to a polymer enhances the free radical scavenging ability of packaging while also inhibiting the escape of the antioxidants, and thus limiting exposure and/or absorption by an individual. In addition to its use in food or pharmaceutical packaging, methods are disclosed for using the antioxidant coupled polymers in a variety of applications including as coatings on the inside of medical devices, such as stents and catheters, which would substantially reduce free radical damage and/or oxygen depletion during medical procedures. Furthermore, through the coupling of antioxidants to biodegradable polymers, controlled delivery and sustained release of an antioxidant to a subject is possible.

Compositions and methods are disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is GLP-1, exendin or an analog of GLP-1 or exendin. The peptides with incretin hormone activity are administered transepithelially using a transepithelial carrier peptide. The transepithelial peptide contains sufficient amino, guanidine or amidino groups to stimulate transepithelial delivery. In some embodiments, the transepithelial carrier and the peptide with incretin hormone activity are embedded in a pressure sensitive adhesive layer of a plaster or patch.

The invention produces polyethylene alcohol hydrogel dressing containing medicine and chitosan with 60Co gamma-radial or high energy electron beam radial cross linking. Additional, adds in some humectant, plasticizer, medicine, the solvent is the secondary distilled water, physiological saline or phosphate neutral buffer liquid. The product can release medicine slowly and has natural amylose chitosan with biology sterilization activity, it has active sterilization function, at the same time, it has high water quantity, and good water reserving performance, the mechanical intensity is moderate, and the light penetration and air penetration are excellent. It can accord the demands for curing each kind of wound. It can used as the permanent dressing for light skin injuries, and it also can be applied to the temporally close of severe skin organization wound or burn wound.

The present invention relates to sustained-release pharmaceutical compositions for ionic pharmaceutically active substances (excluding ionic prostanoic acid derivatives) containing ionic compounds having opposite charges to those of the active substances and increasing hydrophobicity of the active substances. More specifically, the invention relates to sustained-release pharmaceutical compositions comprising the ionic pharmaceutically active substances and the ionic compounds having opposite charges to those of the active substances and increasing hydrophobicity of the active substances that contain hydrophobic groups in the molecule thereof. The pharmaceutical composition of the invention can exhibit excellent sustained release effect of the active substance, irrespective of water solubility possessed by the ionic pharmaceutically active substances.

Drug-delivery stents capable of providing release of two or more drugs such as everolimus and estradiol are provided. The stents can be used for treating a disease such as restenosis and vulnerable plaque.

The present invention provides a method for the synthesis of unagglomerated, highly dispersed, stable core/shell nanocomposite particles comprised of preparing a reverse micelle microemulsion that contains nanocomposite particles, treating the microemulsion with a silane coupling agent, breaking the microemulsion to form a suspension of the nanocomposite particles by adding an acid/alcohol solution to the microemulsion that maintains the suspension of nanocomposite particles at a pH of between about 6 and 7, and simultaneously washing and dispersing the suspension of nanocomposite particles, preferably with a size exclusion HPLC system modified to ensure unagglomeration of the nanocomposite particles. The primary particle size of the nanocomposite particles can range in diameter from between about 1 to 100 nm, preferably from between about 10 to 50 nm, more preferably about 10 to 20 nm, and most preferably about 20 nm.

Sustained release spherical or non-spherical pellets comprising (a) an active ingredient (b) a wax-like agent, and (c) a spheronizing agent are provided. Oral dosage forms comprising said pellets and methods for preparing and using such pellets and dosage forms are also provided.

The present invention is drawn to solidifying adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug which can treat various skin infections, such as fungal, bacterial, and/or viral skin infections. The formulation can include an anti-infective drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent. The non-volatile solvent system can facilitate the delivery of the drug at therapeutically effective rates for sustained period of time. The non-volatile solvent system can also act as a plasticizer for the solidifying agent. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.

The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent of HMG-CoA reductase inhibitors or erythropoietin. The nanoparticles are characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.

Provided herein in some embodiments is a formulation comprising (a) one or more nanoscale particle; and (b) a film-forming polymer. In some instances, the formulation is an immediate and sustained released formulation suitable for topical administration or administration to surfaces. Also provided here in certain embodiments is a method of reducing the population of pathogenic microorganisms on skin or surfaces, the method comprising applying to the skin or surface a composition, the composition comprising (a) one or more nanoscale particle; and (b) a film-forming polymer.

The invention relates to the technical field of medicine, in particular to a stomach floating type pellet and a preparation method thereof. The stomach floating type pellet comprises a pellet core, a drug layer and a sustained-release layer; the density of the pellet is smaller than 1g/cm<3>, so that the drug can float in the stomach, sustainably release the drug ingredients; stomach floating type capsules can be prepared by loading the pellets into capsules. The preparation type is suitable for drugs mainly absorbed in the stomach, in particular to the drugs that are absorbed better in the stomach than in the enteric canal. When the drugs are prepared into stomach floating type pellets or stomach floating type capsules, compared with ordinary preparation, the times of administration is reduced and the relatively stable blood concentration of the drugs is kept in vivo, thus ensuring the sustained release of the drugs, improving the bioavailability and reducing the dosage. At the same time, as the stomach floating type pellet is a granose system, the drug release behavior is the collective behavior of each pellet, so that coating failure of a plurality of pellets can not lead to failure of the whole dosage, thus having higher safety. The sustained-release pellet is prepared by adopting general technique and is easy for realizing industrial production.